




CYBERDYNE



**Consolidated Financial Result Briefing
for the six months ended September 30, 2024**

**CYBERDYNE, Inc.
November 14, 2024**

Consolidated financial statements

Consolidated six months results summary (IFRS)

Unit: Millions of yen

	FY2023 H1	FY2024 H1	YoY +/-	YoY +/- %
Revenue	2,104	2,143	+39	+1.9%
Core operating profit (loss)*	(683)	(466)	+217	—
Operating profit (loss)	(1,317)	(497)	+819	—
Profit (loss) before tax	(180)	(215)	(35)	—
Profit (loss) attributable to owners of parent	(603)	(305)	+297	—

Revenue

2,143 Million
+39M (+1.9%) YoY

- Treatment service (US RHG etc.) +144M (Business+63, exchange difference+81)
- Rental products -26M (Japan+13, outside Japan-69, exchange difference+30)
- New business (Contracted development of semiconductor subsidiaries, etc. -79M (business-103, exchange difference+24)

Core operating profit

-466 Million
+217 Million YoY

- Treatment service (US RHG etc.) + 184M
- Rental products -89M (Japan -25M, outside Japan -64M)
- New business (three subsidiaries) +14M
- Improvement of RD expenses, head office expenses +108M

Profit (loss) before tax

215 Million
-35 Million YoY

- Operating income difference +819M
- Finance income/expenses and profit or loss related to CEJ Fund YoY -842M (FY2024 +293 - FY2023 +1136 = -842)
- Decrease in investment accounted for using the equity method -12M

* Core operating income = operating income - non-recurring gains/losses (permanent exchange rate = foreign exchange gains/losses due to deviation from the previous year's average, one-time gains/losses such as impairment).

* Foreign exchange gain: +1 million yen and write-down of old product inventory due to product improvement: -33 million yen

Consolidated financial results: Revenue/Operating profit

Increase in revenues and loss improvement in treatment services, etc., such as RHG in the U.S.

Unit: Millions of yen

		FY2023 H1	FY2024 H1	YoY +/-	YoY +/- %
Product rental	Revenue	858	832	-26	-3%
	Operating profit (margin%)	406 (47%)	333 (40%)	-73	-18%
Treatment service	Revenue	802	946	+144	+18%
	Operating profit (margin%)	-236 (-28%)	-62 (-7%)	+174	-
New business expansion	Revenue	444	365	-79	-18%
	Operating profit (margin%)	-175 (-20%)	-170 (-47%)	+5	-
RD expenses and head office expenses	Adjusted amount	-1,311	-598	+713	-
Consolidated total (IFRS)	Revenue	2,104	2,143	+39	+2%
	Operating profit (margin%)	-1,317 (-63%)	-497 (-23%)	+819	-

* Operating income by business segment is the amount of profit or loss, which is revenue minus operating expenses, for each business.

* RD expenses and head office expenses are adjustment amounts of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Rental of product: Rental income from the Group's product (include income from sold products)
- Treatment service: Income from treatment at the Group's rehabilitation facilities (including Robocare)
- New business expansion: Revenue from new business area of the Group (subsidiary company in mobility and sleep apps)

Revenue by geographical regions and type of transaction

Increase in rental for Japan and treatment service in US RHG

Unit: Millions of yen
Top: 2024 H1
Bottom: (2023 H1)

Type	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	456 (442)	137 (154)	220 (224)	19 (37)	832 (858)	-26 (-3%)
Treatment service	63 (75)	21 (24)	0 (0)	862 (703)	946 (802)	+144 (+18%)
New business expansion	144 (211)	220 (232)	0 (0)	0 (0)	365 (444)	-79 (-18%)
Total	663 (729)	379 (410)	220 (224)	880 (740)	2,143 (2,104)	+39 (+2%)
YoY	-66 (-9%)	-31 (-8%)	-4 (-2%)	+140 (19%)		

AMER: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Pacific * Revenue from Japan is stated separately

Rental revenue by each products

Increase of rental of HAL for Medical Use Lower Limb Type in Japan

Unit: Millions of yen
 Top: 2024 H1
 Bottom: (2023 H1)


	Type of products	Japan	Outside Japan	Total
Cybernetics Treatment (Functional Improvement/ regeneration)	HAL Lower Limb Type (Medical)	183 (163)	268 (261)	450 (424)
	HAL Lower Limb Type (Non-Medical)	80 (79)	0 (0)	80 (79)
	HAL Single Joint Type	44 (45)	52 (49)	96 (94)
Care and Well-being support	HAL Lumbar Type	51 (55)	43 (51)	95 (106)
Labor support	HAL Lumbar Type	19 (22)	0 (0)	19 (22)
	Mobility Robot (CL02 etc.)	39 (53)	0 (0)	39 (53)
Other (Acoustic X, HAL Peripherals, Consumables)		41 (27)	13 (54)	54 (80)
Total		456 (442)	376 (415)	832 (858)

Outline of the business

Realization of “Techno-peer Support Society”


A future society where people and technology coexists, cooperates and mutually support each other

For wide variety of people faced with health, physical function, cognitive and psychological problems
 A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernetics: Fuses and combines humans, AI-Robots and Information Systems



***Cybernetics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernetics as pioneering cutting-edge innovative science and technology areas

Business in the integrated space of "Human" + "Cyber/Physical Space"

Improving the well-being of seniors and people with disability

Medical HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist, and ankle joints

HCPS Human Collaborative Robotics

Cybernetics Space
Fusion of "Human" + "Cyber/Physical Space"

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cyin for Living Support
Helps communication of patients in severe condition

Improving the well-being through supporting and supervising solutions

Medical HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist, and ankle joints

HCPS Human Collaborative Robotics

Cybernetics Space
Fusion of "Human" + "Cyber/Physical Space"

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cyin for Living Support
Helps communication of patients in severe condition

Towards the 5th Industrial Revolutions! "Human" + "Cyber/Physical Space" HCPS Fusion Technology Cybernetics Industry that will follow Robot and IT Industry

Prevention/Early Detection/Medical&Healthcare



Improving well-being of seniors and people with disability



Improving well-being through supervising and live support solutions



Work support and improving efficiency through AI automation



Prevention, early detection and medical/healthcare

LED array light source that enables real time photoacoustic imaging

Medical HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist, and ankle joints

HCPS Human Collaborative Robotics

Cybernetics Space
Fusion of "Human" + "Cyber/Physical Space"

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cyin for Living Support
Helps communication of patients in severe condition

Work support and improving efficiency through AI automation

Medical HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist, and ankle joints

HCPS Human Collaborative Robotics

Cybernetics Space
Fusion of "Human" + "Cyber/Physical Space"

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level


Transportation Robot
Autonomous robot that can carry heavy loads on its own

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Future of medical healthcare and healthy life

Prevention/early detection, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life



Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

【Medical】Cybernetics Treatment (functional improvement/rehabilitation treatment)


Cybernetics Treatment: Developed as innovative method utilizing HAL for treating brain-nerve-musculoskeletal disorders



HAL Lumbar Type

HAL Single Joint Type

HAL Lower Limb Type




*The treatment services operated by the Group are classified as “service sales” and “rental sales” in cases where products are rented based on rental contract

【Prevention/Early detection, Diagnosis check】

Super small vital sensor “Cyvis”

Daily medical health check with “Cyvis”


One device to accumulate, analyze and AI process various vital data



* Application for medical device certification has been filed (April 2023) and certification is expected to be granted soon. Currently in test marketing.

【Prevention and early detection】 Ultra small vital sensor Cyvis

Expands remote service that connects households to hospitals and facilities




Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)



Adopted as the cover of Biophotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!

Example of application


- Routine examination and diagnosis of diabetic foot lesions
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device

【Medical】 Global Dissemination of Cybernics Treatment

Strategy to promote Cybernics as a global platform


Strengthening cooperation with politics/government/academia/related industries around the world



EMEA : Europe, Middle East and Africa

Social implementation of Cybernics Treatment (Malaysia)

Collaboration with Malaysian government-affiliated organizations to promote Cybernics Treatment



Social implementation of Cybernics Treatment (Malaysia)

INTERNATIONAL CONFERENCE on CYBERNICS HAL 2023

2023.10.13 Kuala Lumpur Malaysia



Strengthening international collaboration by bringing together clinicians, researchers, and other experts from around the world who work with Cybernics

Social implementation of Cybernics Treatment (Malaysia)

The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia

PERKESO National Neuro-Robotic and Cybernics Rehab. Centre



- ✓ Construction underway in Ipoh, Perak, Northern part of Malaysia (Scheduled by the end of 2024)
- ✓ First phase project
 - ✓ 15.6 Hectare (Approx. 3.4 baseball stadiums)
 - ✓ Gross floor area is approximately 86,400 square meters
- ✓ Capable of accommodating 700 patients at any given time



Strategic base for social implementation of Cybernics Industry, such as HAL, Cybernics Products and technologies of other companies that CYBERDYNE invests through C-Startup

https://www.perkeso.gov.my/images/kenyataan_media/2023/190203_-_LAWATAN_MENTERI_SUMBER_MANUSIA_KE_TAPAK_PUSAT_REHABILITASI_PERKESO_PERAK.pdf?TSPD_101_R0=08e2dacad5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e10251d84d1723291abc11ccb8adcf6ab4640a6f84d8e56752b7e7c10ac4d5baf7b


Social implementation of Cybernics Treatment (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCISO/PERKESO (Malaysia Public Social Security Organization)

SOCISO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (12 facilities)



★ SOCISO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT



<https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129>

Social implementation of Cybernics Treatment (Malaysia)

Top-level meeting towards social implementation of Cybernics Treatment in Malaysia (5/23)

The Minister of Human Resources visited the company and expressed his intention to install 50 HAL sets (65 units) and other large-scale Cybernics products in the new center (currently finalizing the contract)



From the left, Dr. Hafez Bin Hussain, CEO Sankai, Minister Steven Sim Chee Keong, Secretary General Khairul Dzaimie Bin Daub, Dr. Mohammed Azman Bin Aziz Mohammed Group CEO



Minister Steven Sim Chee Keong visiting Cyberdyne HQ

Global Expansion of Cybernics and Strengthening of International Collaboration (APAC)

Presented Cybernics to parliamentarians in Asia and the Middle East as solutions to challenges associated with the aging society.

2024.4.23 Parliamentarians' Meeting on ICPD30* : Leaving No One Behind in an Ageing World



2024.4.24 Asian Forum of Parliamentarians on Population and Development (AFPPD) Standing Committee Meeting on Active Ageing



Main agendas

- Addressing Population Aging from a Gender Perspective
- AI and Digital Technologies to Support Healthy Aging
- Policy Priorities for Creating a Senior-friendly Society
- Emerging Population Trends and the Economic Sustainability in the Asia-Pacific Region with the ageing population

*30 years anniversary of the International Conference on Population and Development

<https://afppd.net/afppdwp/wp-content/uploads/2024/05/Standing-Committee-Meeting-of-Active-Ageing-Tokyo-final-min.pdf>

https://www.mofa.go.jp/mofaj/press/release/press1_001636.html

Global Expansion of Cybernics and Strengthening of International Collaboration (APAC)



Reinforced collaboration between Cybernics and Top class academia of Taiwan

2024.9.5-6 Taiwan

2024.9.5 National Taiwan University
“Royal Palm Lecture Series”



https://www.ntu.edu.tw/spotlight/2024/2301_20240918.html

2024.9.6 Fu Jen Catholic University Hospital



President Francis Yi-Chen Lan, Deputy Director Dr. Horng-Huei Liou,
And other medical staff of the hospital



President Wen-Chang Chen

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)

2024.1.12 Hannover Germany

Cybernics & Neurobionics Summit 2024 (Jointly hosted with International Neuroscience Institute)

Gathering the world's leading pioneers in cutting-edge developments in Cybernics and neurobionics



Joint hosts
Dr. Madjid Samii (center) - Founder of INI, President of INI
Dr. Amir Samii (right) - Vice President of INI

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)

AGEVITY 2024 (in collaboration with Italy, which has the highest aging index in the EU)

2024.9.25 Milan Italy

Creating innovation in the “longevity economy”



Platform born out of the Silver Economy Network with the support of Assolombarda, the main organizing body of the Confindustria (Confederation of Italian Industry)

Promoting public-private partnership policies and projects to improve, promote, and protect longevity in Italy today and in the future

2024.4.9 Assolombarda Silver Economy Network visited Cyberdyne Head Office



*Silver Economy Network: a national network (more than 100 participating institutions) dedicated to developing innovative projects, services, and products in the context of the Silver Economy and longevity.

AGEVITY 2024
LONGEVITY | SOCIETY | ECONOMY | FUTURE

24-25 September 2024
Bocconi University

vi 16:50 – 17:50 **Ensuring longevity for today's and tomorrow's societies: global perspectives Innovation and business**

→Presentation by CEO Sankai

<https://agevity.com/en/>

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)

Shared the latest information and exchanged views on future developments in the field of Cybernics and issues in the field of medicine and health associated with the aging of society with European Parliamentarians



2024.2.9
Speaker of the Parliament of the Kingdom of Sweden, Mr. Andreas Noreen, a delegation of parliamentarians, and the Swedish Ambassador to Japan



2024.7.11
Delegation of the German Bundestag Committee on Education, Research and Technology Assessment

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)



CYBERNICX FUTURE : A Step into the Future

2024.10.30 Istanbul Turkey

Physicians, medical industry leaders, and academia promoting Cybernics Treatment gathered to discuss innovative developments in health tech and to exchange ideas on collaboration




Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)



10th Annual Meeting of the Serbian Neurosurgical Society

2024.11.1 Serbia, Belgrade

Deepened collaboration of Cybernics with European Neurosurgical Societies



Prof. Dr. Lukas Rasulic

Honorary President of the 10th SNSS Annual Meeting
President of the Serbian Neurosurgical Society
Secretary of the European Association of Neurosurgical societies

November 1st - **Exhibition Hall**

14.15-16.45 General Scientific Session 2

Moderators: Lukas Rasulic, Djula Djilvesi

14.15-14.45 Cybernics Medical and Healthcare Innovation making full use of Cybernics and Neurobionics
[Yoshiyuki Sankai](#)

14.45-15.05 The use of intraoperativ MRI in pediatric brain tumor surgery

[Amir Samii](#) **Joint Host of Cybernics & Neurobionics Summit 2024**

15.05-15.25 Building Bridges Across Continents: Lessons from the FANS Global &

Global Expansion of Cybernics and Strengthening of International Collaboration (AMER)

11th Annual Brain Mapping Day US Congress

June 5, 2024 Washington DC, USA

Building relationships with U.S. legislators - policy makers - medical professionals to accelerate U.S. deployment of Cybernics Technology



Dr. Babak Kateb
(Society for Brain Mapping & Therapeutics Chairman)



Keynote speech by CEO Sankai



“Advances in the Treatment of Physical-Motor Disability”,

2024.11.14 Rio de Janeiro Brazil

Collaboration with the Brazilian Medical Association: sharing the latest research findings in the treatment of physical movement disorders and HTLV

Status of indication of HAL Lower Limb Type for spinal cord diseases

2022/10 Japan - Extention to two diseases
(2023/10 Listed for public health insurance coverage)

Viral: HTLV-1 associated myelopathy (HAM)
Hereditary: spastic paraplegia

2024/5 US FDA - Expanded indication to two diseases stated above

Hosted by the Brazilian National Academy of Medicine
International symposium tributed to the World HTLV Day



SIMPÓSIO
AVANÇOS NO TRATAMENTO DAS DEFICIÊNCIAS FÍSICO-MOTORAS.
HOMENAGEM AO DIA MUNDIAL DE COMBATE AO HTLV.
14 DE NOVEMBRO DE 2024.

7:10 pm Cybernics Treatment with HAL for Neuromuscular Diseases including HAM caused by HTLV-1

Yoshiyuki Sankai - University of Tsukuba; CYBERDYNE Inc. ; SIP Program, Cabinet Office, Japan

HTLV-1-associated myelopathy (HAM)

A subset of patients infected with human T-cell leukemia virus type 1 (HTLV-1), the causative virus of adult T-cell leukemia/lymphoma (ATL), **show progressive paralysis of both lower limbs** and urinary and defecation disorders

In Japan, about half of the patients are located in Kyushu, Shikoku, and Okinawa

Worldwide, patients are found in **the Caribbean, South America**, Southwest Africa, South India, inland Iran, European countries, and the United States.

<https://www.anm.org.br/simposio-avancos-no-tratamento-da-deficiencia-fisico-motora/>

Medical device approval for Medical HAL Lower Limb Type

Expansion of cleared diseases in USA (Disease/Size)

As of September 30, 2024

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	<ul style="list-style-type: none"> • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia 	(application in progress)
USA		Approved	Approved	Approved	<ul style="list-style-type: none"> • Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia 	Approved
EMEA	Europe	Approved	Approved	Approved		(application in progress)
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	(application in progress)	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Development pipeline (1)

1) Medical HAL (Lower Limb Type) : Clinical trials etc.

As of September 30, 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Neuromuscular Disease (8 types of disease such as ALS and muscular dystrophy)								FY2022 revision (DPC calculation) Planning for public health insurance Planning for insurance reimbursement
Spinal related disease (2 diseases virus and hereditary)								Public health insurance approved Applying for expansion of target diseases Obtained medical device clearance
Spinal Cord Injury								Communicating with regulators Preparing trial towards public health insurance (Germany) Planning for insurance reimbursement
Stroke								Preparing for additional clinical trial Planning for public health insurance Planning for insurance reimbursement
Cerebral Palsy								Investigator-initiated clinical trial
Multiple Sclerosis								

2023/10
 MHLW approves insurance reimbursement
 • HTLV-1 Associated Myelopathy (HAM)
 • Hereditary spastic paraplegia

2024/5 !!
 US FDA clears three additional diseases
 • Cerebral Palsy*
 • HTLV-1 Associated Myelopathy (HAM)
 • Hereditary Spastic Paraplegia

*Above 12 years old

Public workers
 Compensation
 insurance (Germany)

Clinical trials to be conducted on the premise of German public medical insurance coverage

G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage

G-BA approves Cybernics Treatment **as the standard of care to be considered for spinal cord injury patients** (in accordance with §137eSGB V of the Study Regulations)

G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by **public health insurance for Cybernics Treatment in advance**).

The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Protocol for Clinical Trials

2023/01 Protocol outline presented

2023/03 Expert hearing held

2023/09 Protocol guideline announced

2024/11 CRO selection completed



G-BA (Federal Joint Committee): Organization at the federal level that determines basic benefits, prices, standards, etc. for German insurance treatment.

§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes final evaluations of promising treatments that could become the standard of care.

Development pipeline (2)

2) Medical HAL (Lumbar Type) : Clinical trials etc.

As of September 30 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Parkinsons Disease 								Currently designing a protocol for clinical trials while confirming efficacy through pilot studies

*Topics: Started working on Parkinson's disease, a disease with over nine million patients worldwide

*Considering medical device approval for stroke in a form that combines usage of HAL Lumbar Type with other types of HAL


Cybernetics Medical Innovation Base: Outline

Reinforcing CYBERDYNE's growth strategy
Accelerate the fusion of bio- and medical-related technologies with AI, robotics, and information technologies

Innovation center based on Cybernetics Technology and regenerative medicine/drug discovery



Kingsky Front Tonomachi, Kawasaki
New base with a view to global expansion
(5 minutes from Haneda Airport)



Life science companies such as C-Startup partners in regenerative medicine and drug discovery move in
New fusion R&D will be promoted!

Cybernetics Medical Innovation Base: Purpose

1) Combined Cybernetics Treatment : Regenerative Medicine and HAL

While "Cybernetics Treatment" using the world's first Wearable Cyborg HAL is becoming a standard treatment for functional improvement and regeneration of human brain nerves and muscles (HAL is already available in 20 countries in Europe, the U.S., Asia, etc.), **further therapeutic effects are expected for severe patients by introducing technology at the cellular level and cell-produced substances.** The Group will promote the systemization of Cybernetics Treatment at this research facility.

2) Combined Cybernetics Treatment : Drug and HAL

After the post-marketing study of "Cybernetics Treatment" using the Wearable Cyborg HAL, **the combination of the latest nucleic acid drugs and HAL** has begun in actual medical practice, and **synergistic effects from the combined therapy of drugs and HAL are hoped for.** CYBERDYNE will promote the systematization of Cybernetics Treatment in cooperation with pharmaceutical companies and the institutions occupying such research facilities.

3) Integration of medical and bio-based technologies with AI, robotics, and information systems

In addition to deploying the Group's **new-generation robotic bioreactor technologies and technologies that integrate medical/biotechnologies with AI, robotics, and information technologies,** the company will provide research facilities to partner companies (**medical/biotechnological companies and start-ups** that can collaborate with the Company) and others to develop new medical technologies and expand the Company's business.

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.